Tirzepatide : Treatment For Diabetes Mellitus II & Obesity
DOI:
https://doi.org/10.37591/rrjodfdp.v10i2.1339Keywords:
Tirzepatide, Diabetes, Obesity, Pharmacological Activity, antidiabetic Drugs.Abstract
Tirzepatide is a novel medication that the FDA has approved to treat type 2 diabetes mellitus. Tirzepatide is used off-label to treat obesity because` of its powerful weight-loss effects. It Known as the "twin epidemics," the prevalence of obesity and diabetes is a growing issue worldwide, particularly in wealthy nations. Therefore, cutting-edge therapeutic strategies are required. Tirzepatide, Known as a "twincretin," tirzepatide is the only dual glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP) receptor agonist that is considered a "first-in-class" medication. It has the ability to significantly lower blood sugar levels and enhance insulin sensitivity, as well as improve lipid metabolism and reduce body weight by more than 20%. To enhance the advantages of GLP-1 drugs like semaglutide, it functions as a dual GLP-1 agonist and GIP agonist.. It is currently administered as a once-weekly subcutaneous injectable as a second-line diabetic medicine, much as GLP-1 drugs. In May 2022, Tirzepatide received FDA approval. The gastrointestinal side effects, such nausea or diarrhea, are the most frequently reported side effects..This exercise goes over the tirzepatide dosage guidelines, mechanism of action, side effects, contraindications, and key information. It also emphasizes for all practitioners the tirzepatide administration, monitoring, and toxicity connected with the drug. With a C20 fatty acid segment added, this novel anti-diabetic drug is a synthetic peptide mimic of the human GIP hormone. Using acylation technology, it can bind to albumin and provide a weekly subcutaneous injection dose of the medication that is suitable for its roughly five-day half-life.References
Vivek P. Chavda, Jinal Ajabiya, Divya Teli, Joanna Bojarska and Vasso Apostolopoulos ; Tirzepatide, a New Era of Dual-Targeted Treatment for Diabetes and Obesity: A Mini-Review
Bokvist BK, Coskun T, Cummins RC, Alsina- Fernandez J, "GIP and GLP-1 co-agonist compounds",US patent 9474780, issued 2016-10-25, assigned to Eli Lilly and Co
Sagonowsky, Eric (26 October 2021). "As Lilly gears up for key 2022 launches, Trulicity,Taltz and more drive solid growth". Fierce Pharma. Archived from the original on 14 May 2022. Retrieved 9 April 2022.
Kellaher, Colin (28 April 2022). "Eli Lilly's Tirzepatide Meets Main Endpoints in Phase 3 Obesity Study". MarketWatch. Dow Jones Newswires. Archived from the original on 29 April 2022.Retrieved 29 April 2022.
Francis S Willard, et al. JCI Insight. 2020 Sep 3;5(17):e140532. [6] Coskun T, et al. Mol Metab. 2018 Dec;18:3-14.
Bucheit J, Ayers J, Pamulapati L, Browning A, Sisson E. A Novel Dual Incretin Agent, Tirzepatide (LY3298176), for the Treatment of Type 2 Diabetes Mellitus and Cardiometabolic Health. J Cardiovasc Pharmacol. 2022 Aug 01;80(2):171-179.
Coskun T, Sloop KW, Loghin C, Alsina-Fernandez J, Urva S, Bokvist KB, Cui X, Briere DA, Cabrera O, Roell WC, Kuchibhotla U, Moyers JS, Benson CT, Gimeno RE, D'Alessio DA, Haupt A: LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept. Mol Metab. 2018 Dec;18:3-14. doi: 10.1016/j.molmet.2018.09.009. Epub 2018 Oct 3.
Frias JP: Tirzepatide: a glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) dual agonist in development for the treatment of type 2 diabetes. Expert Rev Endocrinol Metab. 2020 Nov;15(6):379-394. doi: 10.1080/17446651.2020.1830759. Epub 2020 Oct 8.
Min T, Bain SC: The Role of Tirzepatide, Dual GIP and GLP-1 Receptor Agonist, in the Management of Type 2 Diabetes: The SURPASS Clinical Trials. Diabetes Ther. 2021 Jan;12(1):143-157. doi: 10.1007/s13300-020-00981-0. Epub 2020 Dec 15.
Straight Healthcare
Frederick, M.O.; Boyse, R.A.; Braden, T.M.; Calvin, J.R.; Campbell, B.M.; Changi, S.M.; Coffin, S.R.; Condon, C.; Gowran,O.; McClary, J.; et al. Kilogram-scale GMP manufacture of tirzepatide using a hybrid SPPS/LPPS approach with continuous manufacturing. Org. Process Res. Dev. 2021, 25, 1628–1636.
May, S.A.; Johnson, M.D.; Buser, J.Y.; Campbell, A.N.; Frank, S.A.; Haeberle, B.D.; Hoffman, P.C.; Lambertus, G.R.; McFarland,A.D.; Moher, E.D.; et al. Development and manufacturing GMP scale-up of a continuous ir-catalyzed homogeneous reductiveamination reaction. Org. Process Res. Dev. 2016, 20, 1870–1898.
Wang, Z.; Wang, Z.; Lin, S.; Jin, H.; Gao, S.; Zhu, Y.; Jin, J. Nanoparticle-templated nanofiltration membranes for ultrahigh performance desalination. Nat. Commun. 2018, 9, 2004–2013.
FDA Approved Drug Products: MOUNJARO (tirzepatide) Injection, for subcutaneous use
Tirzepatide (Mounjaro) for type 2 diabetes. Med Lett Drugs Ther. 2022 Jul 11;64(1654):105-107. [PubMed]
Farzam K, Jan A. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): Dec 27, 2022. Beta Blockers. [PubMed]
Trujillo J. Safety and tolerability of once-weekly GLP-1 receptor agonists in type 2 diabetes. J Clin Pharm Ther. 2020 Sep;45 Suppl 1(Suppl 1):43-60. [PMC free article] [PubMed]
LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. National Institute of Diabetes and Digestive and Kidney Diseases; Bethesda (MD): Jun 20, 2022. Tirzepatide. [PubMed]
Bethel MA, Diaz R, Castellana N, Bhattacharya I, Gerstein HC, Lakshmanan MC. HbA1c Change and Diabetic Retinopathy During GLP-1 Receptor Agonist Cardiovascular Outcome Trials: A Meta-analysis and Meta-regression. Diabetes Care. 2021 Jan;44(1):290-296. [PMC free article] [PubMed]
Chavda VP, Ajabiya J, Teli D, Bojarska J, Apostolopoulos V. Tirzepatide, a New Era of Dual-Targeted Treatment for Diabetes and Obesity: A Mini-Review. Molecules. 2022 Jul 05;27(13) [PMC free article] [PubMed]
LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. National Institute of Diabetes and Digestive and Kidney Diseases; Bethesda (MD): Jun 20, 2022. Tirzepatide. [PubMed]
Frías JP, Davies MJ, Rosenstock J, Pérez Manghi FC, Fernández Landó L, Bergman BK, Liu B, Cui X, Brown K., SURPASS-2 Investigators. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. N Engl J Med. 2021 Aug 05;385(6):503-515. [PubMed]
Min T, Bain SC. The Role of Tirzepatide, Dual GIP and GLP-1 Receptor Agonist, in the Management of Type 2 Diabetes: The SURPASS Clinical Trials. Diabetes Ther. 2021 Jan;12(1):143-157.
Kroopnick JM, Davis SN. The role of Recent Pharmacotherapeutic Options on the Management of Treatment Resistant Type 2 Diabetes. Expert Opin Pharmacother. 2022 Aug;23(11):1259-1271. [PubMed] [26] Coskun T, Sloop KW, Loghin C, Alsina-Fernandez J, Urva S, Bokvist KB, Cui X, Briere DA, Cabrera O, Roell WC, Kuchibhotla U, Moyers JS, Benson CT, Gimeno RE, D'Alessio DA, Haupt A: LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept. Mol Metab. 2018 Dec;18:3-14. doi: 10.1016/j.molmet.2018.09.009. Epub 2018 Oct 3. (PubMed ID 30473097)
www.drugbank.com
Drugs and Lactation Database (LactMed®) [Internet]. National Institute of Child Health and Human Development; Bethesda (MD): Jun 20, 2022. Tirzepatide. [PubMed]. [29]https://naomedical.com/health/tirzepatide-overdose-symptoms-treatment-prevention/?amp=1
Jastreboff A.M., Aronne L.J., Ahmad N.N., Wharton S., Connery L., Alves B., Kiyosue A., Zhang S., Liu B., Bunck M.C., et al. Tirzepatide once weekly for the treatment of obesity. N. Engl. J. Med. 2022;11:127. doi: 10.1056/NEJMoa2206038. [PubMed] [CrossRef] [Google Scholar]
Downloads
Published
Issue
Section
License
Declaration and Copyright Transfer Form
(to be completed by authors)
I/ We, the undersigned author(s) of the submitted manuscript, hereby declare, that the above manuscript which is submitted for publication in the STM Journals(s), is not published already in part or whole (except in the form of abstract) in any journal or magazine for private or public circulation, and, is not under consideration of publication elsewhere.
- I/We will not withdraw the manuscript after 1 week of submission as I have read the Author Guidelines and will adhere to the guidelines.
- I/We Author(s ) have niether given nor will give this manuscript elsewhere for publishing after submitting in STM Journal(s).
- I/ We have read the original version of the manuscript and am/ are responsible for the thought contents embodied in it. The work dealt in the manuscript is my/ our own, and my/ our individual contribution to this work is significant enough to qualify for authorship.
- I/We also agree to the authorship of the article in the following order:
Author’s name
1. ________________
2. ________________
3. ________________
4. ________________
| We Author(s) tick this box and would request you to consider it as our signature as we agree to the terms of this Copyright Notice, which will apply to this submission if and when it is published by this journal. |
